- The FDA has approved the use of Eli Lilly And Co's LLY Lyumjev (insulin lispro-aabc injection) 100 units/mL with Insulet Corporation's PODD insulin management systems.
- Lyumjev, approved by the FDA in June 2020, is a formulation of insulin lispro to speed insulin absorption into the bloodstream.
- As rapid-acting insulin, Lyumjev helps control glucose levels after meals in adults with diabetes.
- The FDA has approved an expanded label for the rapid-acting insulin with Insulet's Omnipod & Omnipod DASH insulin pumps.
- Price Action: LLY shares are down 1.54% at $268.29, while PODD shares are up 1.85% higher at $292.90 during the market session on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
